Terms ending in 2042
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,433,951 | Methods of Treatment of Non-Small-Cell Lung Carcinoma Using Telisotuzumab Vedotin In force · High confidence | AbbVie Manufacturing Management Unlimited Company | In force | High confidence | |
| US 11,633,497 | Anti-C-Met Antibody Drug Conjugates In force · High confidence | AbbVie Manufacturing Management Unlimited Company | In force | High confidence | |
| US 11,759,527 | Anti-EGFR Antibody-Drug Conjugates In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,639,393 | ANTI-CCR8 Antibodies In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,767,310 | Nicotinamide RIPK1 Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,802,149 | Anti-Amyloid Beta Antibodies and Methods of Using the Same In force · High confidence | AbbVie Inc. | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by AbbVie Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.